Showing 5291-5300 of 6661 results for "".
- Almirall and Inserm Transfert Collaborate to Develop Innovative Treatments for Vitiligohttps://practicaldermatology.com/news/almirall-and-inserm-transfert-collaborate-to-develop-innovative-treatments-for-vitiligo/2461198/Almirall, S.A. and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), have entered into a licensing agreement and research collaboration to advance treatment options for vitiligo. The partnership, signed by
- Murad Joins Forces with Sesame to Offer Skin Care Consults with Dermatologists, Primary Care Doctorshttps://practicaldermatology.com/news/murad-joins-forces-with-sesame-to-offer-skin-care-consults-with-dermatologists-primary-care-doctors/2461194/Murad is partnering with Sesame to introduce skin consultations with board-certified dermatologists and primary care clinicians. <
- New Two-Year Data on Deucravacitinib Reinforce Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-two-year-on-bms-deucravacitinib-data-reinforce-efficacy-and-safety-profile-in-treatment-of-moderate-to-severe-plaque-psoriasis/2461191/Bristol Myers Squibb shared new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through u
- Indoor Tanning Ban Could Slash Melanoma Deathshttps://practicaldermatology.com/news/indoor-tanning-ban-could-slash-melanoma-deaths/2461190/An indoor tanning ban in England would reduce melanoma deaths, according to a study by University of Manchester researchers. By tracking the projected impact on the 618,000 18-year-olds living in England in 2019, the research team showed that a ban on indoor tanning would resu
- Handheld Device May Painlessly Identify Skin Cancershttps://practicaldermatology.com/news/handheld-device-may-painlessly-identify-skin-cancers/2461188/Researchers at Stevens Institute of Technology are developing a low-cost handheld device that could cut the rate of unnecessary biopsies in half and give dermatologists and other frontline physicians easy access to laboratory-grade cancer diagnostics. “We aren’t trying
- DermTech Seeks to #Stickit2Melanomahttps://practicaldermatology.com/news/dermtech-seeks-to-stickit2melanoma/2461184/DermTech is bringing back its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech’s core mission to help end deaths from melanoma through early and reliable detection. For every
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn